T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured
SØBORG, Denmark, April 12, 2024 (GLOBE NEWSWIRE) -- Cbio A/S – Pioneering Next-Gen T-Cell Therapies for Solid Tumors, Unveils 2023 Financial Results and Company Updates.
- SØBORG, Denmark, April 12, 2024 (GLOBE NEWSWIRE) -- Cbio A/S – Pioneering Next-Gen T-Cell Therapies for Solid Tumors, Unveils 2023 Financial Results and Company Updates.
- Ulrik Cordes, Founder & CEO of Cbio, stated: “2023 was another great year for Cbio.
- We finalized the preclinical development of our lead T-cell therapy asset, novoleucel and made considerable progress in preparing for our upcoming phase I/II clinical trial at Karolinska, where we will treat 20 patients with late-stage cervical cancer.
- Ulrik Cordes continues: “Our top priority for 2024 is to start our first clinical trial, thereby reaching a major value inflection point.